France-based global healthcare investor, Archimed, has closed its MED IV fund at the €1.5bn (US$1.75bn) hard cap. MED IV, launched in January 2026 with an original target of €1.2bn, was three times oversubscribed, and follows on from the €650m MED III fund. It will pursue the series’ smallcap healthcare buyout strategy, building a diversified, global portfolio.
“The momentum behind MED IV reflects investors’ confidence in our approach,” says Denis Ribon, chairman and managing partner at Archimed.
The fund attracted a broad group of existing and current investors – largely institutional limited partners, including pension funds, insurance companies and sovereign wealth funds. Europe and North America represent 80% of MED IV’s investor base (equally split); the rest of the world accounts for the remainder, according to Baptiste Mélinon, partner and head of Investor Relations.
MED IV will invest primarily through majority control transactions alongside founders, families and management teams, in the firm’s prioritised healthcare sectors, including Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services and MedTech.
